– TSX:FRX.TO
stock price today
stock price monthly change
stock price quarterly change
stock price yearly change
key metrics
Market Cap | 232.86M |
Enterprise value | 307.18M |
P/E | -9.8 |
EV/Sales | N/A |
EV/EBITDA | -14.64 |
Price/Sales | N/A |
Price/Book | 111.43 |
PEG ratio | -0.82 |
EPS | 0.08 |
Revenue | 44.95M |
EBITDA | 7.47M |
Income | 2.84M |
Revenue Q/Q | 1413.23% |
Revenue Y/Y | 1299.50% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 16.63% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freestock price history
stock forecast
financial statements
| Jun 2023 | 3.32M | -5.44M | -163.73% |
|---|---|---|---|
| Sep 2023 | 6.51M | -1.86M | -28.66% |
| Dec 2023 | 9.73M | -2.68M | -27.55% |
| Mar 2024 | 25.37M | 12.83M | 50.59% |
| Sep 2025 | 17.78M | 3.61M | 20.3% |
|---|---|---|---|
| Dec 2025 | 25.24M | 5.91M | 23.44% |
| Dec 2025 | 19.33M | 4.77M | 24.7% |
| Mar 2026 | 22.40M | 0 |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 19437000 | 29.16M | 150.04% |
|---|---|---|---|
| Sep 2023 | 19028000 | 29.55M | 155.34% |
| Dec 2023 | 26864000 | 38.48M | 143.26% |
| Mar 2024 | 69193000 | 66.17M | 95.64% |
| Jun 2023 | -3.94M | 0 | 514K |
|---|---|---|---|
| Sep 2023 | -2.76M | 0 | 201K |
| Dec 2023 | -4.86M | 0 | 5.73M |
| Mar 2024 | 39.04M | 0 | -1.13M |
alternative data
| Aug 2023 | 36 |
|---|---|
| Sep 2023 | 36 |
| Oct 2023 | 36 |
| Nov 2023 | 36 |
| Dec 2023 | 36 |
| Jan 2024 | 36 |
| Feb 2024 | 36 |
| Mar 2024 | 36 |
| Apr 2024 | 36 |
| May 2024 | 29 |
| Jun 2024 | 29 |
| Jul 2024 | 29 |
other data
| Insider | Compensation |
|---|---|
Mr. Rostislav Raykov (1976) Chief Executive Officer & Director | $430,000 |
| Ms. Shubh Goel (1974) Chief Commercial Officer | $360,000 |
Mr. Robert C. Andrade (1975) Chief Financial Officer | $311,750 |
-
What's the price of stock today?
One share of stock can currently be purchased for approximately $5.6.
-
When is 's next earnings date?
Unfortunately, 's (FRX.TO) next earnings date is currently unknown.
-
Does pay dividends?
No, does not pay dividends.
-
How much money does make?
has a market capitalization of 232.86M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1284.5% to 21.25M US dollars.
-
What is 's stock symbol?
null is traded on the TSX under the ticker symbol "FRX.TO".
-
What is 's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ?
Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 's key executives?
's management team includes the following people:
- Mr. Rostislav Raykov Chief Executive Officer & Director(age: 49, pay: $430,000)
- Ms. Shubh Goel Chief Commercial Officer(age: 51, pay: $360,000)
- Mr. Robert C. Andrade Chief Financial Officer(age: 50, pay: $311,750)
-
How many employees does have?
As Jul 2024, employs 29 workers, which is 19% less then previous quarter.
-
When went public?
null is publicly traded company for more then 24 years since IPO on 12 Jun 2001.
-
What is 's official website?
The official website for is fennecpharma.com.
-
Where are 's headquarters?
is headquartered at 68 TW Alexander Drive, Research Triangle Park, NC.
-
How can i contact ?
's mailing address is 68 TW Alexander Drive, Research Triangle Park, NC and company can be reached via phone at +91 96364530.
company profile:
TSX
29
Biotechnology
Healthcare
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Research Triangle Park, NC 27709
:
ISIN: CA31447P1009
:
